Hidenori Yaku

Hidenori Yaku

Auto-generated profile, based on publicly available information

Hidenori Yaku

Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TKTakao Kato
Takao Kato
HYHidenori Yaku
Hidenori Yaku
TMTakeshi Morimoto
Takeshi Morimoto
YIYasutaka Inuzuka
Yasutaka Inuzuka
YTYodo Tamaki
Yodo Tamaki
TKTakeshi Kimura
Takeshi Kimura
Background: Despite the prognostic importance of hypoalbuminemia, the prognostic implication of a change in albumin levels has not been fully investigated during hospitalization in patients with acute decompensated heart failure (ADHF). Methods: Using the data from the Kyoto Congestive Heart Failure registry on 3160 patients who were discharged alive for acute heart failure hospitalization and in whom the change in albumin levels was calculated at discharge, we evaluated the association with an increase in serum albumin levels from admission to discharge and clinical outcomes by a multivariable Cox hazard model. The primary outcome measure was a composite of all-cause death or hospitalization for heart failure. Findings: Patients with increased albumin levels (N = 1083, 34.3%) were younger and less often had smaller body mass index and renal dysfunction than those with no increase in albumin levels (N = 2077, 65.7%). Median follow-up was 475 days with a 96% 1-year follow-up rate. Relative to the group with no increase in albumin levels, the lower risk of the increased albumin group remained significant for the primary outcome measure (hazard ratio: 0.78, 95% confidence interval: 0.69–0.90: P = 0.0004) after adjusting for confounders including baseline albumin levels. When stratified by the quartiles of baseline albumin levels, the favorable effect of increased albumin was more pronounced in the lower quartiles of albumin levels, but without a significant interaction effect (interaction P = 0.49). Conclusions: Independent of baseline albumin levels, an increase in albumin during index hospitalization was associated with a lower 1-year risk for a composite of all-cause death and hospitalization in patients with acute heart failure.

24 February 2023 in American Heart Journal
Verified
Journal Article
Closed access
HYHidenori Yaku
Hidenori Yaku
TKTakao Kato
Takao Kato
TMTakeshi Morimoto
Takeshi Morimoto
KKKazuhisa Kaneda
Kazuhisa Kaneda
RNRyusuke Nishikawa
Ryusuke Nishikawa
TKTakeshi Kimura
Takeshi Kimura

16 February 2024 in Journal of Cardiology
Verified
Journal Article
Closed access
HYHidenori Yaku
Hidenori Yaku
MFMarat Fudim
Marat Fudim
SSSanjiv J. Shah
Sanjiv J. Shah

1 October 2022 in Journal of Cardiology
Verified
Journal Article
Closed access
HYHidenori Yaku
Hidenori Yaku
KKKazuhisa Kaneda
Kazuhisa Kaneda
JKJun Kitamura
Jun Kitamura
TKTakao Kato
Takao Kato
TKTakeshi Kimura
Takeshi Kimura

24 April 2020 in Circulation Journal
Verified
Journal Article
Open access
PDF file
YTYasuaki Takeji
Yasuaki Takeji
TTTomohiko Taniguchi
Tomohiko Taniguchi
TMTakeshi Morimoto
Takeshi Morimoto
NSNaritatsu Saito
Naritatsu Saito
KAKenji Ando
Kenji Ando
OIon behalf of the CURRENT AS Registry Investigators and K-TAVI Registry Investigators
on behalf of the CURRENT AS Registry Investigators and K-TAVI Registry Investigators
Background:There are no data comparing transcatheter aortic valve implantation (TAVI) with surgical aortic valve replacement (SAVR) outcomes in real clinical practice in Japan. Methods and Results:We combined 2 independent registries, the K-TAVI Registry (a 6-center prospective registry of consecutive patients who underwent TAVI) and the CURRENT AS Registry (a large, 27-center registry of 3,815 consecutive patients with severe aortic stenosis [AS]). In the K-TAVI Registry, 338 patients underwent TAVI with SAPIEN XT balloon-expandable valves from October 2013 to January 2016, whereas in the CURRENT AS Registry 237 patients with severe AS underwent SAVR from January 2003 to December 2011. Propensity score matching was conducted, with final cohort comprising 306 patients. The cumulative 2-year incidence of all-cause death and heart failure (HF) hospitalization did not differ significantly between the TAVI and SAVR groups (13.7% vs. 12.4% [P=0.81] and 7.9% vs 3.9% [P=0.13], respectively). After adjusting for residual confounders, there were no significant differences between the TAVI and SAVR groups in the risk for all-cause death (hazard ratio [HR] 0.74; 95% confidence interval [CI] 0.35–1.58; P=0.43) or HF hospitalization (HR 1.27; 95% CI 0.40–4.59; P=0.69). Conclusions:These findings from 2 independent Japanese registries suggest that the 2-year risk of all-cause mortality and HF does not differ significantly between TAVI and SAVR groups in real-world practice in Japan.

22 April 2022 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
TKTetsuma Kawaji
Tetsuma Kawaji
TATakanori Aizawa
Takanori Aizawa
SHShun Hojo
Shun Hojo
HYHidenori Yaku
Hidenori Yaku
KNKenji Nakatsuma
Kenji Nakatsuma
SMShinji Miki
Shinji Miki